These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

823 related articles for article (PubMed ID: 18288745)

  • 1. Patent foramen ovale closure with the Intrasept occluder: Complete 6-56 months follow-up of 247 patients after presumed paradoxical embolism.
    Spies C; Timmermanns I; Reissmann U; van Essen J; Schräder R
    Catheter Cardiovasc Interv; 2008 Feb; 71(3):390-5. PubMed ID: 18288745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Percutaneous transcatheter closure of patent foramen ovale with the Amplatzer Cribriform septal occluder.
    Silvestry FE; Naseer N; Wiegers SE; Hirshfeld JW; Herrmann HC
    Catheter Cardiovasc Interv; 2008 Feb; 71(3):383-7. PubMed ID: 18288733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interventional closure with Amplatzer PFO occluder of patent foramen ovale in patients with paradoxical cerebral embolism.
    Chatterjee T; Petzsch M; Ince H; Rehders TC; Körber T; Weber F; Schneider H; Auf der Maur C; Nienaber CA
    J Interv Cardiol; 2005 Jun; 18(3):173-9. PubMed ID: 15966921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome after percutaneous closure of a patent foramen ovale using the Intrasept device: a multi-centre study.
    Luermans JG; Post MC; Schräder R; Sluysmans T; Vydt T; Vermeersch P; Chessa M; Onorato E; Goy JJ; Budts WI
    Catheter Cardiovasc Interv; 2008 May; 71(6):822-8. PubMed ID: 18324695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of contemporary devices used for transcatheter patent foramen ovale closure.
    Spies C; Reissmann U; Timmermanns I; Schräder R
    J Invasive Cardiol; 2008 Sep; 20(9):442-7. PubMed ID: 18762672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patent foramen ovale closure in patients with cryptogenic thrombo-embolic events using the Cardia PFO occluder.
    Spies C; Strasheim R; Timmermanns I; Schraeder R
    Eur Heart J; 2006 Feb; 27(3):365-71. PubMed ID: 16254007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcatheter closure of patent foramen ovale with the Spider patent foramen ovale occluder: a prospective, single-center trial.
    Zhang CJ; Huang YG; Huang XS; Huang T; Huang WH; Shen JJ; Xun ZR
    Chin Med J (Engl); 2010 Apr; 123(7):834-7. PubMed ID: 20497673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Causes of recurrent focal neurologic events after transcatheter closure of patent foramen ovale with the CardioSEAL septal occluder.
    Kutty S; Brown K; Asnes JD; Rhodes JF; Latson LA
    Am J Cardiol; 2008 May; 101(10):1487-92. PubMed ID: 18471463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of transcatheter patent foramen ovale closure in patients with paradoxical embolism.
    Cifarelli A; Musto C; Parma A; Pandolfi C; Pucci E; Fiorilli R; De Felice F; Nazzaro MS; Violini R
    Int J Cardiol; 2010 Jun; 141(3):304-10. PubMed ID: 19178959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ASD and PFO closure with the Solysafe septal occluder - results of a prospective multicenter pilot study.
    Ewert P; Söderberg B; Dähnert I; Hess O; Schuler G; Bussmann C; Bernhard J; Sick P
    Catheter Cardiovasc Interv; 2008 Feb; 71(3):398-402. PubMed ID: 18288739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcatheter closure of patent foramen ovale (PFO) in patients with paradoxical embolism. Periprocedural safety and mid-term follow-up results of three different device occluder systems.
    Braun M; Gliech V; Boscheri A; Schoen S; Gahn G; Reichmann H; Haass M; Schraeder R; Strasser RH
    Eur Heart J; 2004 Mar; 25(5):424-30. PubMed ID: 15033255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percutaneous closure of patent foramen ovale in patients with presumed paradoxical embolism: periprocedural results and midterm risk of recurrent neurologic events.
    Balbi M; Casalino L; Gnecco G; Bezante GP; Pongiglione G; Marasini M; Del Sette M; Barsotti A
    Am Heart J; 2008 Aug; 156(2):356-60. PubMed ID: 18657668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results after fluoroscopy-guided closure of patent foramen ovale for secondary prevention of paradoxical embolism.
    Wahl A; Kunz M; Moschovitis A; Nageh T; Schwerzmann M; Seiler C; Mattle HP; Windecker S; Meier B
    Heart; 2008 Mar; 94(3):336-41. PubMed ID: 17639093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcatheter closure of patent foramen ovale associated with paradoxical embolism using the amplatzer PFO occluder: initial and intermediate-term results of the U.S. multicenter clinical trial.
    Hong TE; Thaler D; Brorson J; Heitschmidt M; Hijazi ZM;
    Catheter Cardiovasc Interv; 2003 Dec; 60(4):524-8. PubMed ID: 14624434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percutaneous closure of patent foramen ovale with a bioabsorbable occluder device: single-centre experience.
    Ussia GP; Cammalleri V; Mulè M; Scarabelli M; Barbanti M; Scardaci F; Mangiafico S; Immè S; Capodanno D; Tamburino C
    Catheter Cardiovasc Interv; 2009 Oct; 74(4):607-14. PubMed ID: 19360875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New onset atrial fibrillation after patent foramen ovale closure.
    Staubach S; Steinberg DH; Zimmermann W; Wawra N; Wilson N; Wunderlich N; Sievert H
    Catheter Cardiovasc Interv; 2009 Nov; 74(6):889-95. PubMed ID: 19626689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resolution of migraine by transcatheter patent foramen ovale closure with Premere Occlusion System in a preliminary series of patients with previous cerebral ischemia.
    Rigatelli G; Cardaioli P; Braggion G; Giordan M; Fabio D; Aggio S; Roncon L; Chinaglia M
    Catheter Cardiovasc Interv; 2007 Sep; 70(3):429-33. PubMed ID: 17722021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent events following patent foramen ovale closure in patients above 55 years of age with presumed paradoxical embolism.
    Spies C; Khandelwal A; Timmemanns I; Kavinsky CJ; Schräder R; Hijazi ZM
    Catheter Cardiovasc Interv; 2008 Dec; 72(7):966-70. PubMed ID: 18942060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transcatheter patent foramen ovale closure in spite of interatrial septum hypertrophy or lipomatosis: a case series.
    Rigatelli G; Dell'Avvocata F; Giordan M; Ronco F; Braggion G; Schenal N; Aggio S; Cardaioli P
    J Cardiovasc Med (Hagerstown); 2010 Feb; 11(2):91-5. PubMed ID: 19829139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exclusion of patients with arteriosclerosis reduces long-term recurrence rate of presumed arterial embolism after PFO closure.
    Dubiel M; Bruch L; Liebner M; Schmehl I; Winkelmann A; Rux S; Sonntag S; Wulff H; Grad MO; Kleber FX
    J Interv Cardiol; 2007 Aug; 20(4):275-81. PubMed ID: 17680857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.